These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 17427044)

  • 41. Minimal clinically important change on the unified Parkinson's disease rating scale.
    Schrag A; Sampaio C; Counsell N; Poewe W
    Mov Disord; 2006 Aug; 21(8):1200-7. PubMed ID: 16673410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Depressive symptoms and motor condition in Parkinson's disease patients].
    Stella F; Bucken-Gobbi LT; Gobbi S; Sant'Ana-Simões C
    Rev Neurol; 2007 Nov 16-30; 45(10):594-8. PubMed ID: 18008264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA; Virley DJ; Perren M; Iravani MM; Jackson MJ; Rose S; Jenner P
    Exp Neurol; 2008 May; 211(1):172-9. PubMed ID: 18321484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Ropinirole in the treatment of Parkinson's disease: an update].
    Vivancos-Matellano F
    Rev Neurol; 2006 May 1-15; 42(9):542-8. PubMed ID: 16676278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.
    Dusek P; Busková J; Růzicka E; Majerová V; Srp A; Jech R; Roth J; Sonka K
    Clin Neuropharmacol; 2010 Jul; 33(4):186-90. PubMed ID: 20661025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study.
    Valldeoriola F; Cobaleda S; Lahuerta J
    Clin Neurol Neurosurg; 2009 Nov; 111(9):742-7. PubMed ID: 19733003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
    Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
    Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
    Lyons KE; Pahwa R
    Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Medical management and social status of elderly Parkinson patients].
    Vieregge P; Körtke D; Meyer-Bornsen C
    Z Gerontol; 1994; 27(4):260-9. PubMed ID: 7975817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
    Zhao H; Ning Y; Cooper J; Refoios Camejo R; Ni X; Yi B; Parks D
    Adv Ther; 2019 Jun; 36(6):1252-1265. PubMed ID: 30963514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neurostimulation for Parkinson's disease with early motor complications.
    Schuepbach WM; Rau J; Knudsen K; Volkmann J; Krack P; Timmermann L; Hälbig TD; Hesekamp H; Navarro SM; Meier N; Falk D; Mehdorn M; Paschen S; Maarouf M; Barbe MT; Fink GR; Kupsch A; Gruber D; Schneider GH; Seigneuret E; Kistner A; Chaynes P; Ory-Magne F; Brefel Courbon C; Vesper J; Schnitzler A; Wojtecki L; Houeto JL; Bataille B; Maltête D; Damier P; Raoul S; Sixel-Doering F; Hellwig D; Gharabaghi A; Krüger R; Pinsker MO; Amtage F; Régis JM; Witjas T; Thobois S; Mertens P; Kloss M; Hartmann A; Oertel WH; Post B; Speelman H; Agid Y; Schade-Brittinger C; Deuschl G;
    N Engl J Med; 2013 Feb; 368(7):610-22. PubMed ID: 23406026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.